WS #16761
Healthcare is providing a defensive anchor in a volatile market. Pfizer raised its 2026 revenue guidance to $62-64 billion and beat adjusted EPS, driven by strong Eliquis sales. Teva raised its outlook on innovative brand strength, and PTC Therapeutics announced a $500 million buyback. These developments suggest that large-cap healthcare names are successfully passing through cost pressures and maintaining pricing power.
Healthcare Defensive Anchor
Healthcare is providing a defensive anchor in a volatile market. Pfizer raised its 2026 revenue guidance to $62-64 billion and beat adjusted EPS, driven by strong Eliquis sales. Teva raised its outlook on innovative brand strength, and PTC Therapeutics announced a $500 million buyback. These developments suggest that large-cap healthcare names are successfully passing through cost pressures and maintaining pricing power.